In the news: Didi buys Uber China, MOFCOM clears AB InBev-SABMiller and the World Bank urges China to deepen healthcare reform

Uber to sell China business to rival Didi talk that investors were pushing for a truce Both companies were burning through cash, giving out free rides and more, with Uber spending an estimated $1 billion a year in China. Uber's CEO said neither companies have been able to turn a profit yet. Uber will continue to operate its own app for now. Shedding its huge losses in China allows it to focus on expansion elsewhere, and could clear the path for an eventual IPO (though the CEO says he will wait as long as possible). Meanwhile, the purchase may complicate Didi's alliance with other startups around the world, including Lyft Inc. in the U.S., Ola in India and Grab in Southeast Asia, all formed to take on Uber at the global stage. China legalizes ride-sharing services The draft auto AML guidelines explained China's auto industry explained MOFCOM clears AB InBev-SABMiller takeover MOFCOM wrote that it conducted extensive regional market share analyses. AB InBev and CR Snow's combined market share was 43% in 2014, and because the transaction will make AB InBev the joint controller of CR Snow (which was 49% held by SABMiller), MOFCOM ruled that AB InBev's enhanced market power will restrict competition, as well as harm downstream distributors. MOFCOM ordered the 49% Snow Beer stake to be sold to China Resources Beer—this divestment was announced on March 2—and formally gave the nod for the AB InBev-SABMiller deal to proceed on Friday. The latest in MOFCOM's remedy supervision How to tackle merger remedies under MOFCOM's new rules Provisions on the Attachment of Restrictive Conditions to Concentrations of Business Operators (Trial Implementation) World Bank pushes for China healthcare reform An inefficient healthcare system lies at the core of all systemic challenges facing the industry, including drug price discrepancies and susceptibility to bribery and corruption in hospitals, bidding processes and supply and distribution networks. The World Bank's report suggests China take 10 years to fully bolster its primary care system and allow private players fair competition with the public sector. Without these measures, the country risks an increase in health expenditure from Rmb3.5 trillion ($529 billion) last year to Rmb15.8 trillion in 2035, the World Bank said. Eli Lilly Interview: Innovation & compliance—active ingredients Drug pricing probes pressure companies Opinion: Are foreign hospitals really encouraged? China's drug price reforms: Much of the same? What the new Drug Administration Law brings Uber to sell China business to rival Didi talk that investors were pushing for a truce Both companies were burning through cash, giving out free rides and more, with Uber spending an estimated $1 billion a year in China. Uber's CEO said neither companies have been able to turn a profit yet. Uber will continue to operate its own app for now. Shedding its huge losses in China allows it to focus on expansion elsewhere, and could clear the path for an eventual IPO (though the CEO says he will wait as long as possible). Meanwhile, the purchase may complicate Didi's alliance with other startups around the world, including Lyft Inc. in the U.S., Ola in India and Grab in Southeast Asia, all formed to take on Uber at the global stage. China legalizes ride-sharing services The draft auto AML guidelines explained China's auto industry explained MOFCOM clears AB InBev-SABMiller takeover MOFCOM wrote that it conducted extensive regional market share analyses. AB InBev and CR Snow's combined market share was 43% in 2014, and because the transaction will make AB InBev the joint controller of CR Snow (which was 49% held by SABMiller), MOFCOM ruled that AB InBev's enhanced market power will restrict competition, as well as harm downstream distributors. MOFCOM ordered the 49% Snow Beer stake to be sold to China Resources Beer—this divestment was announced on March 2—and formally gave the nod for the AB InBev-SABMiller deal to proceed on Friday. The latest in MOFCOM's remedy supervision How to tackle merger remedies under MOFCOM's new rules Provisions on the Attachment of Restrictive Conditions to Concentrations of Business Operators (Trial Implementation) World Bank pushes for China healthcare reform An inefficient healthcare system lies at the core of all systemic challenges facing the industry, including drug price discrepancies and susceptibility to bribery and corruption in hospitals, bidding processes and supply and distribution networks. The World Bank's report suggests China take 10 years to fully bolster its primary care system and allow private players fair competition with the public sector. Without these measures, the country risks an increase in health expenditure from Rmb3.5 trillion ($529 billion) last year to Rmb15.8 trillion in 2035, the World Bank said. Eli Lilly Interview: Innovation & compliance—active ingredients Drug pricing probes pressure companies Opinion: Are foreign hospitals really encouraged? China's drug price reforms: Much of the same? What the new Drug Administration Law brings